Clinical Practice Guidelines (CPG) on EBMonFHIR
1.1.0 - qa-preview

This page is part of the CPG-on-EBMonFHIR Implementation Guide (1.1.0).

Table of Contents

.. 0 Table of Contents
... 1 Clinical Practice Guidelines (CPG) on EBMonFHIR
... 2 Profiles
... 3 Code Systems
... 4 Value Sets
... 5 Extensions
... 6 Examples
... 7 Downloads
... 8 History
... 9 Artifacts Summary
.... 9.1 Cohorts
.... 9.2 CPGComputablePlanDefinition
.... 9.3 CPGRecommendationDefinition
.... 9.4 CPGShareablePlanDefinition
.... 9.5 CPGStrategyDefinition
.... 9.6 Eligibility Criteria
.... 9.7 Outcome Evidence
.... 9.8 PICO Evidence Variable
.... 9.9 Recommendation Action
.... 9.10 Shareable PlanDefinition
.... 9.11 Assessment Action
.... 9.12 Body Positioning Action
.... 9.13 Certainty of Evidence Rating
.... 9.14 Clinical Practice Guideline
.... 9.15 Drug Administration Action
.... 9.16 Evidence Data Set
.... 9.17 Evidence Synthesis Cohorts
.... 9.18 Guideline Bundle
.... 9.19 Guideline Citation
.... 9.20 Intervention Definition
.... 9.21 Net Effect Estimate
.... 9.22 Outcome Definition
.... 9.23 Outcome Evidence Synthesis
.... 9.24 Procedure Action
.... 9.25 Recommendation
.... 9.26 Recommendation Citation
.... 9.27 Recommendation Eligibility Criteria
.... 9.28 Recommendation Justification
.... 9.29 Recommendation Plan
.... 9.30 Study Citation
.... 9.31 Study Cohort
.... 9.32 Study Eligibility Criteria
.... 9.33 Study Outcome Evidence
.... 9.34 Action Combination Method
.... 9.35 ArtifactAssessment Publication Status
.... 9.36 ArtifactAssessment Version
.... 9.37 Characteristic Dosage
.... 9.38 CQFM Artifact Comment
.... 9.39 Dosage Condition
.... 9.40 qualityOfEvidence
.... 9.41 RelativeTime
.... 9.42 strengthOfRecommendation
.... 9.43 Action Combination Method
.... 9.44 Action Selection Behavior Required
.... 9.45 Allergic Disposition SCT
.... 9.46 Assessment
.... 9.47 Assessment Scales
.... 9.48 Body Positioning SNOMED CT
.... 9.49 Clinical Importance of Outcome
.... 9.50 Cochrane PICO
.... 9.51 Cochrane PICO Intervention
.... 9.52 Cochrane PICO Outcome
.... 9.53 Cochrane PICO Population
.... 9.54 Drugs
.... 9.55 Episode Of Care Type
.... 9.56 Guideline Recommendation Status
.... 9.57 Guideline Stage Classification
.... 9.58 Mean Difference Type
.... 9.59 Observations
.... 9.60 Procedures
.... 9.61 Radiologic Finding SCT
.... 9.62 Rating Acceptability
.... 9.63 Rating Benefit And Harms
.... 9.64 Rating Certainty Of Evidence
.... 9.65 Rating Concern Degree
.... 9.66 Rating Consensus
.... 9.67 Rating Equity
.... 9.68 Rating Feasibility
.... 9.69 Rating Preference And Values
.... 9.70 Rating Resources
.... 9.71 Rating Up Rating One Level
.... 9.72 Rating Up Rating Two Levels
.... 9.73 Recommendation Strength
.... 9.74 Relative Effect Type
.... 9.75 Substances SNOMED CT
.... 9.76 Action Combination Method
.... 9.77 CEOsys Code System
.... 9.78 Clinical Importance of Outcome
.... 9.79 Cochrane Core Ontology
.... 9.80 Cochrane PICO Ontology
.... 9.81 Evidence Certainty Rating
.... 9.82 Evidence To Decision Certainty Rating
.... 9.83 Evidence To Decision Certainty type
.... 9.84 Guideline Stage Classification
.... 9.85 Recommendation Strength
.... 9.86 SynthesisType
.... 9.87 All-cause mortality
.... 9.88 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V
.... 9.89 Certainty of Evidence for outcome: mortality of Dexamethasone application
.... 9.90 COVID19 Intensive Care Treatment Guideline
.... 9.91 COVID19 Intensive Care Treatment Guideline
.... 9.92 Dexamethasone Application
.... 9.93 Dexamethasone Application
.... 9.94 Dexamethasone Application (Intravenous)
.... 9.95 Dexamethasone Application (Oral)
.... 9.96 Dexamethasone for critically ill COVID-19 patients
.... 9.97 Dexamethasone Recommendation
.... 9.98 Example Assessment Action
.... 9.99 Example Body Positioning Action
.... 9.100 Example Certainty Of Evidence Rating
.... 9.101 Example DrugAdministration Action
.... 9.102 Example Evidence Data Set
.... 9.103 Example Evidence Synthesis Cohorts
.... 9.104 Example Guideline
.... 9.105 Example Guideline Citation
.... 9.106 Example Intervention
.... 9.107 Example Net Effect Estimate
.... 9.108 Example No DrugAdministration Action
.... 9.109 Example Organization
.... 9.110 Example Outcome
.... 9.111 Example Outcome Evidence Synthesis
.... 9.112 Example Procedure Action
.... 9.113 Example Recommendation Citation
.... 9.114 Example Recommendation Eligibility Criteria
.... 9.115 Example Recommendation Eligibility Criteria
.... 9.116 Example Recommendation Eligibility Criteria
.... 9.117 Example Recommendation Justification
.... 9.118 Example Recommendation plan
.... 9.119 Example Study Citation
.... 9.120 Example Study Cohort
.... 9.121 Example Study Eligibility Criteria
.... 9.122 Example Study Outcome Evidence
.... 9.123 Guideline Recommendation Example
.... 9.124 Mortality Outcome for Dexamethasone application
.... 9.125 No Dexamethasone Application
.... 9.126 No dexamethasone application for non-ventilated COVID-19 patients
.... 9.127 NO Dexamethasone for moderately ill COVID-19 patients
.... 9.128 Population: COVID19 Non-Ventilated
.... 9.129 Population: COVID19 Ventilated
.... 9.130 recommendation
.... 9.131 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.132 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.133 Systemic corticosteroids for the treatment of COVID-19
.... 9.134 Therapy of hospitalized COVID-19 patients